Baseline population characteristics (at the time of TNFi discontinuation)
| Characteristic | All patients N=717 | Patients initiating TNFi in Corrona N=301 (42% of 717) |
|---|---|---|
| Age in years, median (IQR) | 60 (50–69) | 62 (52–69) |
| Women: N (%) | 536 (74.8) | 231 (76.7) |
| Caucasian: N (%) | 641 (89.4) | 245 (81.4) |
| Education: N (%) | ||
| Completed college, n (%) | 419 (61.4) | 175 (60.6) |
| Insurance*: N (%) | ||
| None | 14 (2.0) | 4 (1.3) |
| Medicaid | 25 (3.6) | 12 (4.0) |
| Medicare | 257 (36.7) | 104 (34.8) |
| Private | 520 (74.2) | 227 (75.9) |
| Duration of RA in years, median (IQR) | 8 (4–15) | 8 (4–14.5) |
| Smoking status: N (%) | ||
| Never | 363 (50.6) | 141 (46.8) |
| Former | 263 (36.7) | 120 (39.9) |
| Current | 91 (12.7) | 40 (14.4) |
| BMI | 27.3 (23.8–31.6) | 27.5 (23.7–32.0) |
| Time on first TNF; months, median (IQR) | NA | 9 (4.1–23.2) |
| Medication use | ||
| TNFi monotherapy | 300 (41.8%) | 159 (52.8%) |
| Concomitant MTX | 320 (44.7%) | 99 (32.9%) |
| Concomitant DMARD (other than MTX) | 59 (8.2%) | 23 (7.6%) |
| Concomitant MTX+DMARD | 38 (5.3) | 20 (6.6%) |
| Number of non-biological DMARDS, median (IQR) | 2 (2–3) | 2 (2–3) |
| Recent prednisone (within 3 months) | 188 (27.2%) | 68 (29.3%) |
*Sum may not add to total N as some patients have dual insurance coverage.
BMI, body mass index; DMARD, disease-modifying antirheumatic drugs; MTX, methotrexate; RA, rheumatoid arthritis; TNFi, tumour necrosis factor inhibitor.